Teva Pharmaceutical Industries (NYSE:TEVA) Price Target Raised to $28.00

Teva Pharmaceutical Industries (NYSE:TEVA) had its target price increased by Barclays from $25.00 to $28.00 in a report published on Wednesday morning,Benzinga reports. They currently have an overweight rating on the stock.

TEVA has been the topic of a number of other reports. StockNews.com raised Teva Pharmaceutical Industries from a “buy” rating to a “strong-buy” rating in a report on Thursday, October 17th. UBS Group lifted their price objective on Teva Pharmaceutical Industries from $24.00 to $26.00 and gave the company a “buy” rating in a report on Tuesday, September 3rd. Finally, JPMorgan Chase & Co. upped their price target on shares of Teva Pharmaceutical Industries from $16.00 to $18.00 and gave the stock a “neutral” rating in a report on Monday, October 21st. Two equities research analysts have rated the stock with a hold rating and seven have given a buy rating to the stock. Based on data from MarketBeat.com, Teva Pharmaceutical Industries presently has an average rating of “Moderate Buy” and an average target price of $20.88.

Teva Pharmaceutical Industries Stock Up 0.9 %

NYSE TEVA traded up $0.19 during trading hours on Wednesday, hitting $21.39. 616,161 shares of the company traded hands, compared to its average volume of 9,373,116. The stock has a market capitalization of $24.23 billion, a price-to-earnings ratio of -25.16, a P/E/G ratio of 0.99 and a beta of 0.79. The company has a debt-to-equity ratio of 2.57, a quick ratio of 0.61 and a current ratio of 0.89. Teva Pharmaceutical Industries has a twelve month low of $10.34 and a twelve month high of $21.98. The business’s 50-day moving average is $17.61 and its 200-day moving average is $17.45.

Insider Buying and Selling

In other Teva Pharmaceutical Industries news, EVP Christine Fox sold 19,388 shares of the stock in a transaction that occurred on Wednesday, November 20th. The shares were sold at an average price of $16.87, for a total transaction of $327,075.56. Following the completion of the sale, the executive vice president now owns 44,104 shares of the company’s stock, valued at approximately $744,034.48. This represents a 30.54 % decrease in their position. The transaction was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. 0.55% of the stock is owned by corporate insiders.

Institutional Trading of Teva Pharmaceutical Industries

A number of large investors have recently bought and sold shares of the business. Thrivent Financial for Lutherans grew its holdings in Teva Pharmaceutical Industries by 21.8% during the third quarter. Thrivent Financial for Lutherans now owns 224,511 shares of the company’s stock worth $4,046,000 after buying an additional 40,218 shares in the last quarter. Sio Capital Management LLC bought a new position in shares of Teva Pharmaceutical Industries during the third quarter valued at about $24,314,000. TCW Group Inc. purchased a new position in Teva Pharmaceutical Industries during the third quarter worth about $1,286,000. Two Sigma Advisers LP grew its position in Teva Pharmaceutical Industries by 15.3% in the 3rd quarter. Two Sigma Advisers LP now owns 1,034,500 shares of the company’s stock worth $18,642,000 after purchasing an additional 137,000 shares in the last quarter. Finally, Pitcairn Co. purchased a new stake in Teva Pharmaceutical Industries in the 3rd quarter valued at about $947,000. 54.05% of the stock is currently owned by institutional investors and hedge funds.

Teva Pharmaceutical Industries Company Profile

Teva Pharmaceutical Industries Limited develops, manufactures, markets, and distributes generic medicines, specialty medicines, and biopharmaceutical products in North America, Europe, Israel, and internationally. It offers generic medicines in various dosage forms, such as tablets, capsules, injectables, inhalants, liquids, transdermal patches, ointments, and creams; sterile products, hormones, high-potency drugs, and cytotoxic substances in parenteral and solid dosage forms; and generic products with medical devices and combination products.